Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging

Mark Topoozian; Jeremie Calais; Ely Felker; Anthony Sisk; Samantha Gonzalez; Sean J Lee; Leonard S Marks

doi:10.1016/j.eucr.2023.102461

Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging

Urol Case Rep. 2023 Jun 9:50:102461. doi: 10.1016/j.eucr.2023.102461. eCollection 2023 Sep.

Authors

Mark Topoozian¹, Jeremie Calais², Ely Felker³, Anthony Sisk⁴, Samantha Gonzalez¹, Sean J Lee¹, Leonard S Marks¹

Affiliations

¹ Department of Urology, David Geffen School of Medicine at UCLA, United States.
² Department of Nuclear Medicine, David Geffen School of Medicine at UCLA, United States.
³ Department of Radiology, David Geffen School of Medicine at UCLA, United States.
⁴ Department of Pathology, David Geffen School of Medicine at UCLA, United States.

Abstract

Focal therapy of prostate cancer (PCa) is currently of great interest, but a metric of success. other than biopsy, is not yet available. In a patient with a repeatedly negative MRI and negative systematic biopsies, a scan employing the radioisotope ⁶⁸Ga-PSMA-11 PET/CT identified a PSMA-avid hotspot in the prostate. PSMA-guided biopsy confirmed the diagnosis of a clinically-significant PCa. Following ablation of the lesion with high-intensity focused ultrasound (HIFU), the PSMA-avid lesion disappeared and targeted biopsy confirmed a fibrotic scar with no residual cancer. PSMA imaging may have a role in guiding diagnosis, focal ablation, and follow-up of men with PCa.

Keywords: Focal therapy; HIFU; PSMA; Prostate cancer.

Publication types

Case Reports